An Import Alert Is Not Physical Damage: What Responds When the FDA Shuts an Indian Export Line

On 11 August 2026 the US Food and Drug Administration placed all drugs and drug products offered for import from Shoolin Pharma Chem LLP, Indrad, Mehsana district, Gujarat, on Import Alert 66-40. A week later, on 18 August 2026, the agency issued warning letter 734100 setting out significant Current Good Manufacturing Practice (CGMP) violations for Active Pharmaceutical Ingredients (APIs) the firm manufactured on non-dedicated equipment and supplied to US compounding pharmacies.

Import Alert 66-40 is the detention-without-physical-examination list for drug firms that have not met drug GMPs. Once a firm is on it, consignments arriving at a US port can be detained and refused admission without anyone opening a drum or drawing a sample, and the evidentiary burden moves to the shipper to demonstrate that the cited conditions are resolved. No inspector needs to visit again for the revenue to stop.

The warning letter added a second, slower loss. The FDA said it may withhold approval of new applications or supplements that list the firm as a manufacturer until the violations are addressed and compliance is confirmed. That reaches past shipments already in transit and into every customer filing that names the site, which a finance team usually discovers a quarter later.

Indian programmes for an API site usually carry a Standard Fire and Special Perils policy with a fire loss of profits section, plus marine cargo on outbound consignments. Both are written around physical damage, and neither is engaged by an import alert.

A fire loss of profits section runs on a material damage proviso. The trigger is damage to insured property at the insured premises by a peril insured under the material damage section, with a claim admitted or admitted but for a deductible. An FDA listing damages nothing, so the material damage condition fails and the business interruption section never opens, however complete the revenue stoppage.

Marine cargo fails on the same logic from the other direction. An all-risks cargo wording covers physical loss of or damage to the goods insured. Cargo refused entry arrives intact, and its problem is legal admissibility rather than condition. Two standard cargo exclusions then close the remaining paths:

• Delay. Institute-style wordings exclude loss, damage or expense proximately caused by delay, and that exclusion holds even where the delay is itself caused by an insured peril. Demurrage and container detention while a consignment sits at a US port therefore fall outside a marine cargo policy.
• Inherent vice. Where a regulator's position is that the material was made under deficient conditions, an insurer can argue the defect was in the goods on the day they were loaded.

This is the same coverage gap our guide to non-damage business interruption from utility and telecom outages describes in a different setting. The peril changes, the proximate cause analysis does not. Where the loss reaches the insured through a legal or regulatory instrument rather than through a damaged asset, damage-triggered wordings stay shut.

The first cover with a genuine claim to respond is trade credit, and it responds to a narrow slice of the loss: the money already owed.

A trade credit policy pays on two events, buyer insolvency and protracted default, subject to a credit limit approved for each named buyer. Where a US pharmacy or distributor took delivery before 11 August 2026 and then stopped paying, the exporter has a receivable aged past the waiting period, and that is a covered default provided the debt is undisputed.

The word undisputed carries most of the weight. Trade credit wordings suspend cover on a receivable while the buyer contests it, and payment resumes only once the dispute is resolved in the insured's favour by agreement, arbitration or judgment. A buyer holding refused material will normally assert the goods were not fit for the regulated purpose they were sold for, which converts a credit claim into a quality dispute and parks it.

Two structural points decide how much of the receivable survives:

1. Non-acceptance cover. The standard policy covers goods delivered. Consignments shipped but refused at the border are pre-delivery, and only a non-acceptance or non-shipment extension picks them up, usually at a lower indemnity percentage and with a shorter waiting period. An exporter without that extension carries the in-transit book itself.
2. Limit withdrawal is prospective and immediate. Credit insurers monitor buyer risk continuously and can withdraw or reduce an approved limit for future shipments on notice, so cover for a buyer can disappear in the same week the alert publishes without any exclusion being invoked.

Exporters running Export Credit Guarantee Corporation of India (ECGC) cover alongside or instead of a private credit policy face the same dispute condition and the same delivery boundary, so holding both does not remove the problem.

Material that cleared customs before the listing and now sits in a US warehouse belongs to a third layer. It is out of transit, away from the insured's premises, and unsellable.

A stock throughput policy is the instrument built for this position. It covers stock on a single wording from raw material through transit, storage at any location in the chain, and onward delivery, replacing the seam between a cargo policy and a property policy where losses at overseas warehouses are usually lost. Two features make it worth writing for an API exporter. It can value stock at the insured's selling price rather than at cost, which is the difference between recovering manufacturing spend and recovering the margin lost. And an unnamed-locations sub-limit with a per-location cap insures the third-party warehouses a US distributor uses, which rarely appear on any Indian schedule.

The base trigger is still physical loss or damage, so the alert alone does not open the policy. What matters is the rejection or condemnation extension, which responds where goods are seized, condemned or ordered destroyed by a public authority and pays the value of the stock plus the cost of disposal. Destruction of a regulated API runs through a licensed incineration contractor with witnessed destruction certificates for the customer's quality file, and those costs land somewhere.

Rejection and condemnation extensions are underwritten on the firm's inspection history. Once a warning letter is public, the extension is declined or priced as a certainty, which makes it a purchase to complete well before an inspection.

The warning letter's substance matters for the fourth layer. The FDA cited APIs manufactured on non-dedicated equipment and supplied to US compounding pharmacies. Non-dedicated equipment is the standard cross-contamination finding, because residue from one product carries into the next batch through shared vessels, lines and dryers.

That pushes cost downstream to parties who never bought an Indian policy. A compounding pharmacy that used the API has to identify affected preparations, notify prescribers, and quarantine or destroy stock. The covers that reach that cost are product recall and contaminated products insurance, and three wording questions decide the outcome:

1. What triggers cover. Accidental contamination wordings require a reasonable likelihood of bodily injury or of the product being unfit. A government recall extension is broader, responding where a public authority orders or requests a withdrawal. Buy the extension explicitly; do not assume it is inside the base form.
2. Whose costs are paid. First-party recall expense covers the insured's own withdrawal costs. Third-party recall liability, also called customer recall costs, covers the sums the insured is legally liable to pay a customer who conducted the recall. For a bulk API supplier the second is usually the larger number, since the recall happens at the formulator.
3. Loss of gross profit after the event. Better contaminated-products wordings carry a business interruption section triggered by the contamination event rather than by damage, one of the few genuine non-damage BI triggers available to a manufacturer in this market.

Product liability is a separate question, and on the published facts it has not been engaged, since liability wordings need bodily injury or property damage and no injury has been reported. Our guide to global product liability coverage for Indian pharmaceutical exporters sets out how the US-facing tower should be built before a claimant appears.

The fifth layer covers people. Where the manufacturer is an LLP, its designated partners hold the same exposure a company's directors would.

A directors and officers liability policy responds to claims alleging wrongful acts in the management of the firm. After a public warning letter the realistic sources are a customer alleging the firm misrepresented its compliance status when the supply agreement was signed, an investor or lender where the firm carries external capital, and Indian proceedings that follow the loss of an export market. The sections that carry the weight are investigation costs cover, which funds representation before an authority ahead of any formal allegation, and defence costs incurred outside India where a US proceeding names an individual.

The timing trap matters more than the limit. D&O is claims-made, and every proposal asks whether the insured is aware of any fact or circumstance that might give rise to a claim. A Form 483 observation or an internal quality review recording a repeat CGMP deviation is exactly such a circumstance. Disclosed, it draws an exclusion at renewal for anything arising from it. Undisclosed, it gives the insurer a non-disclosure argument that can reach the whole policy.

Once a warning letter is public, the market reprices the programme through exclusions rather than through rate alone. The common form is a specific-matter exclusion naming the inspection, the observations or the alert, sometimes bounded by a remediation period that runs until the firm demonstrates compliance and the listing is lifted. A single event feeds every wording at once:

• Trade credit. Buyer limits for the affected market are withdrawn prospectively, and any default the insurer traces to the alert falls outside cover. What remains insured is the unaffected book.
• Stock throughput. The rejection and condemnation extension is carved back for consignments manufactured on the cited equipment or during the cited period, which is most of the stock the exporter actually holds.
• Recall and contaminated products. A prior-knowledge exclusion attaches from the date of the observations, so a later recall arising from the same root cause is a known circumstance rather than an accident.
• D&O. The specific-matter exclusion names the warning letter, and every claim traceable to the regulatory failure sits outside the tower for as long as it stands.

A remediation-period exclusion therefore takes out all four instruments that answered the non-damage loss, at the renewal that follows the event. The exclusion language repays a line-by-line read, particularly on how it defines the excluded matter, whether it extends to related or arising-out-of losses, and what evidence lifts it.

Everything described here is a pre-inspection purchase. The sequence that works is short and has to be run while the compliance file is clean.

1. Ask each insurer, in writing, what triggers business interruption. If the answer is physical damage to insured property, that policy is not part of the regulatory-stoppage answer and should not be counted in a board paper as if it were.
2. Add the rejection and condemnation extension to a stock throughput placement, with an unnamed-locations sub-limit sized to the largest third-party warehouse holding, and selling-price valuation on finished API.
3. Extend trade credit to non-acceptance, so consignments refused at the border are inside the policy, and agree in advance what documentation converts a quality assertion into a resolved dispute.
4. Buy the government recall extension and third-party recall costs on the contaminated products wording, with an indemnity period long enough to cover requalification at the formulator.
5. Notify circumstances the day a Form 483 is issued, under the D&O and any claims-made liability policy then in force.
6. Agree with underwriters in advance what evidence of corrective action lifts a specific-matter exclusion, before one is needed.

Sites building for the US market should read this together with our analysis of insuring a US plant ahead of the 2028 generic tariff, and property teams should size the same site's damage-triggered programme using bulk drug and API plant property underwriting.

Where the wording work sits

Every decision above turns on a clause rather than a product name: whether the stock throughput form carries a rejection and condemnation extension, whether the contaminated products wording includes government recall and third-party recall costs, whether the D&O form funds investigation costs before an allegation. Those clauses vary widely between insurer forms.

Sarvada makes insurer wordings searchable so brokers and risk managers can compare them clause by clause. For an exporter whose largest single-event exposure is a regulator's signature, that means testing which forms respond to a non-damage stoppage before the next inspection instead of discovering the policy wording answer during a detention.

If you place pharmaceutical export risk or advise an API manufacturer selling into regulated markets, Request Access to Sarvada to compare insurer wordings side by side.